Delivery Order SPE2DB20D3505-SPE2DB23FU4K4
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,027.36, is for the delivery of 120 tablets of 1.2 gram Mesalamine delayed-release (DR) tablets. The contract is a firm fixed-price delivery order with an ultimate completion date of March 26, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,735.80 Firm Fixed Price delivery order is for the supply of 120 tablets of Mesalamine DR 1.2 GM, a medication used to treat inflammatory bowel diseases. The contract has an ultimate completion date of May 15, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which has an...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The $1,238.51 firm fixed-price delivery order contract is for the supply of MESALAMINE DR 1.2 GM TABLET 120S, a pharmaceutical product. The contract has an ultimate completion date of May 28, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is a Delivery Order worth $4,389.16 for the supply of 120 tablets of Mesalamine Delayed Release 1.2 grams. The contract has an ultimate completion date of July 24, 2024 and is a Firm Fixed Price arrangement. This award is likely part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,797.58 firm fixed-price delivery order is for Mesalamine 800 mg delayed-release tablets and has a completion date of February 23, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $18,170.87, is for the delivery of 4,563,198,346 units of Mesalamine 800 mg delayed-release tablets. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,345.03 delivery order contract is for the supply of 4559435723 - Mesalamine DR 1.2 GM Tablet 120S, with a completion date of December 22, 2022. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,594.32 Firm Fixed Price delivery order is for the supply of 4566550847 MESALAMINE DR 1.2 GM TABLET 120S. The contract has an ultimate completion date of November 27, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, involves the delivery of 4,557,190,652 units of the drug Mesalamine DR 1.2 GM Tablet 120S. The $10,065.29 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency. The contract has a May 12, 2022 completion date and was awarded on May 11, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc. This award is part of a larger...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 4,563,713,896 tablets of the medication Mesalamine DR 1.2 gram, with a ceiling value of $5,692.07. The contract is a firm fixed price delivery order with a period of performance extending to February 21, 2024. This award is part of a larger Indefinite...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB23FU4K4Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of 4,561,559,448 tablets of Mesalamine DR 1.2 GM. The total ceiling value of the delivery order is $3,846.35, with a firm fixed price. The contract has an ultimate completion date of July 21, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 7/20/23 |